Eisai licenses Gliadel Wafer to Nobelpharma

Japanese drugmaker Eisai has licensed the domestic rights to develop and commercialize Gliadel Wafer (polifeprosan 20 with carmustine implant)  to Nobelpharma. Financial terms of the deal were not disclosed.

The agent is the only US-approved chemotherapeutic implant for use  during surgical procedures for malignant glioma. It has been cleared in  18 countries worldwide, primarily in North America, Europe, and  Southeast Asia. The National Comprehensive Cancer Network Clinical  Practice Guidelines in Oncology refer to the use of carmustine wafers  as part of the treatment strategy for the disease.

Malignant gliomas are difficult to treat. Eisai expects that the timely  development of Gliadel Wafer by Nobelpharma, which is actively committed  to progressing drugs for highly unmet medical needs that are strongly  desired by patient advocacy groups or academic society.